MCID: FXF002
MIFTS: 30

Fox-Fordyce Disease

Categories: Endocrine diseases, Rare diseases, Skin diseases

Aliases & Classifications for Fox-Fordyce Disease

MalaCards integrated aliases for Fox-Fordyce Disease:

Name: Fox-Fordyce Disease 12 53 44 15
Fox Fordyce Disease 12 73
Fox-Fordyce Syndrome 53
Foxfordyce Disease 76
Miliaria, Apocrine 53
Apocrine Miliaria 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1381
ICD10 33 L75.2
ICD9CM 35 705.82
MeSH 44 D005588
NCIt 50 C84716
SNOMED-CT 68 65038009
UMLS 73 C0016632

Summaries for Fox-Fordyce Disease

NIH Rare Diseases : 53 Fox-Fordyce disease is a chronic skin disease most common in women aged 13-35 years. It is characterized by the development of intense itching in the underarm area, the pubic area, and around the nipple of the breast as a result of perspiration which becomes trapped in the sweat gland and surrounding areas. The cause is unknown, but heat, humidity, and stress may play a role. Treatment may include the use of retinoids, antibiotics, and immunosuppressants.

MalaCards based summary : Fox-Fordyce Disease, also known as fox fordyce disease, is related to miliaria and xanthomatosis. An important gene associated with Fox-Fordyce Disease is OSMR (Oncostatin M Receptor), and among its related pathways/superpathways is Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and lung.

Wikipedia : 76 Fox�??Fordyce disease, or apocrine miliaria, is a chronic blockage of the sweat gland ducts with a... more...

Related Diseases for Fox-Fordyce Disease

Diseases related to Fox-Fordyce Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 miliaria 30.1 CD68 CEACAM5 PIP
2 xanthomatosis 10.5
3 hidradenitis 10.3
4 hidradenitis suppurativa 10.2
5 turner syndrome 10.2
6 liver leiomyoma 10.1 CEACAM5 KIT
7 adenoid basal cell carcinoma 10.0 CEACAM5 KIT
8 aggressive digital papillary adenocarcinoma 10.0 CEACAM5 KIT
9 rete testis adenocarcinoma 10.0 CEACAM5 KIT
10 warthin tumor 10.0 CEACAM5 KIT
11 rete testis neoplasm 10.0 CEACAM5 KIT
12 ceruminoma 10.0 KIT PIP
13 cutaneous adenocystic carcinoma 10.0 CEACAM5 PIP
14 mastocytosis, cutaneous 10.0 KIT OSMR
15 nodular hidradenoma 10.0 CEACAM5 PIP
16 vulval paget's disease 10.0 CEACAM5 PIP
17 extragonadal seminoma 10.0 CEACAM5 KIT
18 mixed cell type cancer 10.0 CEACAM5 KIT
19 eccrine adenocarcinoma 10.0 CEACAM5 PIP
20 vulva adenocarcinoma 10.0 CEACAM5 PIP
21 gastric signet ring cell adenocarcinoma 10.0 CEACAM5 PIP
22 papillary hidradenoma 10.0 KIT PIP
23 blepharochalasis 10.0 CD68 OSMR
24 thyroid carcinoma, familial medullary 10.0 CEACAM5 OSMR
25 axillary lipoma 9.9 CD68 KIT
26 gastrointestinal system cancer 9.9 CEACAM5 KIT
27 extracutaneous mastocytoma 9.9 CD68 KIT
28 lymphohistiocytoid mesothelioma 9.9 CD68 CEACAM5
29 conventional fibrosarcoma 9.9 CD68 KIT
30 acute salpingitis 9.9 CD68 MRAP
31 liver sarcoma 9.9 CD68 CEACAM5
32 mesenteric lymphadenitis 9.9 CD68 MRAP
33 thyroid cancer, nonmedullary, 2 9.9 CEACAM5 OSMR
34 gastrointestinal system disease 9.9 CEACAM5 KIT
35 clear cell acanthoma 9.9 CD68 CEACAM5
36 congenital epulis 9.9 CD68 CEACAM5
37 xanthogranulomatous cholecystitis 9.9 CD68 CEACAM5
38 central nervous system melanocytic neoplasm 9.9 CD68 KIT
39 connective tissue cancer 9.8 CD68 KIT
40 small cell cancer of the lung 9.8 CEACAM5 KIT

Graphical network of the top 20 diseases related to Fox-Fordyce Disease:



Diseases related to Fox-Fordyce Disease

Symptoms & Phenotypes for Fox-Fordyce Disease

Drugs & Therapeutics for Fox-Fordyce Disease

Drugs for Fox-Fordyce Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 785)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
3
Treprostinil Approved, Investigational Phase 4 81846-19-7 54786 6918140
4
Acetylcholine Approved Phase 4,Not Applicable 51-84-3 187
5
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
6
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
7
Iloprost Approved, Investigational Phase 4,Phase 1,Phase 2 78919-13-8 6443959
8
Nicotine Approved Phase 4,Phase 2,Not Applicable 54-11-5 942 89594
9
Pramipexole Approved, Investigational Phase 4,Phase 2 104632-26-0 119570 59868
10
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
11
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
12
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
13
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 81-81-2 6691 54678486
14
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
15
Insulin Glargine Approved Phase 4,Not Applicable 160337-95-1
16
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-66-6
17
Caffeine Approved Phase 4,Phase 1 58-08-2 2519
18
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
19
Amantadine Approved Phase 4,Phase 2 768-94-5 2130
20
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
21
Ropinirole Approved, Investigational Phase 4,Phase 2 91374-21-9, 91374-20-8 497540 5095
22
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
23
Phentolamine Approved Phase 4 50-60-2 5775
24
Zoledronic acid Approved Phase 4,Phase 3 118072-93-8 68740
25
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
26
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
27
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
29
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
30
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
31
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
32 Ixazomib Approved, Investigational Phase 4,Phase 1,Phase 2 1072833-77-2
33
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
34
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1 134678-17-4 60825
35
Ibuprofen Approved Phase 4 15687-27-1 3672
36
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
37
Cefazolin Approved Phase 4 25953-19-9 656510 33255
38
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
39
Pseudoephedrine Approved Phase 4 90-82-4 7028
40
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
41
Phenylephrine Approved Phase 4 59-42-7 6041
42
Ephedrine Approved Phase 4 299-42-3 9294
43
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
46
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 56-40-6 750
47
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 56-45-1 5951
48 Tezosentan Investigational Phase 4 180384-57-0
49
Lactitol Investigational Phase 4 585-86-4 3871
50 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1529)
# Name Status NCT ID Phase Drugs
1 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
2 Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain Unknown status NCT01615627 Phase 4 HypotonicTreprostinil Solution;Eutonic Treprostinil Solution
3 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
5 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
6 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes Completed NCT00353834 Phase 4 Exenatide;Glargine Insulin
7 A Study to Determine if Caffeine Accelerates Emergence From Anesthesia Completed NCT02567968 Phase 4 Caffeine;Placebo Control
8 Effects of White Wine vs. Tea Intake During and an Alcoholic Digestive Following a High Fat, High Calorie Cheese Fondue Meal on Gastric Emptying and Abdominal Symptoms in Healthy Volunteers Completed NCT00943696 Phase 4
9 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
10 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
11 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4 Methylphenidate (MPD);Placebo
12 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
13 Spy II Clinical Registry Completed NCT00751998 Phase 4
14 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
15 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4 Fesoterodine 8 mg;Placebo
16 Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging Completed NCT01221272 Phase 4 Ranolazine;Placebo to match ranolazine
17 Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers Recruiting NCT03495609 Phase 4 Ovitrelle
18 Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients Recruiting NCT02583399 Phase 4 Ibuprofen
19 Kunxian for the Treatment of Rheumatoid Arthritis Recruiting NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
20 Prevention of Infections in Cardiac Surgery (PICS) Prevena Study Recruiting NCT03402945 Phase 4 Cefazolin;Vancomycin
21 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
22 Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator Recruiting NCT01742299 Phase 4 STI571
23 Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea Recruiting NCT02630121 Phase 4 Oxymetazoline Hydrochloride;Placebo
24 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Recruiting NCT02942407 Phase 4 apixaban;warfarin
25 Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules Recruiting NCT03502070 Phase 4 Placebo
26 STATIN: Web-based Investigation of Side Effects Recruiting NCT02781064 Phase 4 Atorvastatin 20mg;Placebo
27 Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Not yet recruiting NCT03205566 Phase 4 Raltegravir 400Mg Tab;Lamivudine 150Mg Tablet
28 Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Unknown status NCT02527772 Phase 2, Phase 3 Liposomal Doxorubicin+Gemcitabine;FOLFOX4
29 Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer Unknown status NCT00084552 Phase 3
30 Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Unknown status NCT02534337 Phase 2, Phase 3 GEMOX;FOLFOX4
31 Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Unknown status NCT00516464 Phase 3 Lucentis (ranibizumab)
32 Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients Unknown status NCT01333358 Phase 3 Alemtuzumab
33 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
34 Boost Use in Breast Conservation Radiotherapy Unknown status NCT00138814 Phase 3
35 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
36 A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis Unknown status NCT00628680 Phase 3 Heparin
37 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
38 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
39 Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization Unknown status NCT00438867 Phase 3
40 Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation Unknown status NCT00691470 Phase 2, Phase 3 ATI-5923;Coumadin (warfarin)
41 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
42 Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00062309 Phase 3
43 Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer Completed NCT00244868 Phase 3
44 Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer Completed NCT00352638 Phase 3
45 Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Completed NCT00003313 Phase 3 amifostine trihydrate;carboplatin;paclitaxel
46 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
47 The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction Completed NCT00143507 Phase 3 Ivabradine;Placebo
48 Study of APD421 as PONV Treatment (Prior Prophylaxis) Completed NCT02646566 Phase 3 APD421;Placebo
49 Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer Completed NCT00767286 Phase 3 flutamide;goserelin acetate
50 S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer Completed NCT00004011 Phase 3 carboplatin;paclitaxel

Search NIH Clinical Center for Fox-Fordyce Disease

Cochrane evidence based reviews: fox-fordyce disease

Genetic Tests for Fox-Fordyce Disease

Anatomical Context for Fox-Fordyce Disease

MalaCards organs/tissues related to Fox-Fordyce Disease:

41
Skin, Breast, Lung, Liver, Thyroid, Testis

Publications for Fox-Fordyce Disease

Articles related to Fox-Fordyce Disease:

(show top 50) (show all 83)
# Title Authors Year
1
Fox-Fordyce disease. ( 29641729 )
2018
2
Can Fractionated Microneedle Radiofrequency be an Effective Procedure for Treatment of Fox-Fordyce Disease? A Medical Hypothesis. ( 29862220 )
2018
3
Fox-Fordyce disease: report of two cases with perifollicular xanthomatosis on histological image. ( 30066765 )
2018
4
Fox-Fordyce Disease: An under-diagnosed adverse event of laser hair removal? ( 27135989 )
2016
5
Fox-Fordyce disease of the vulva. ( 27190415 )
2016
6
A female case of Fox-Fordyce disease. ( 27226051 )
2016
7
A novel modality using microwave technology for the treatment of Fox-Fordyce disease (FFD). ( 27051811 )
2016
8
In vivo features of Fox-Fordyce disease in high-definition optical coherence tomography. ( 26713641 )
2016
9
Successful treatment of areolar Fox-Fordyce disease with surgical excision and 1550-nm fractionated erbium glass laser. ( 27072751 )
2016
10
Fox-Fordyce Disease. ( 26909204 )
2016
11
In vivo features of Fox-Fordyce disease in high-definition optical coherence tomography. ( 26972218 )
2016
12
Effective treatment of Fox-Fordyce disease with pulsed dye laser. ( 27623097 )
2016
13
Fox-Fordyce disease: a report of 2 cases responding to topical clindamycin. ( 25566917 )
2015
14
Axillary syringomas mimicking Fox-Fordyce disease. ( 26500884 )
2015
15
Successful treatmeant of refractory pruritic Fox-Fordyce disease with botulinum Toxin Type A. ( 26385128 )
2015
16
Clinical Effects of Topical Tacrolimus on Fox-Fordyce Disease. ( 26171257 )
2015
17
Lesions in the axilla after hair removal using intense pulsed light. Fox-Fordyce disease. ( 24838226 )
2015
18
Fox-Fordyce disease treatment with fractional CO2 laser. ( 24261728 )
2013
19
Fox Fordyce disease as a secondary effect of laser hair removal. ( 24131099 )
2013
20
Fox-Fordyce disease with an atypical clinical presentation. ( 23260875 )
2013
21
Fox-Fordyce disease: response to adapalene 0.1%. ( 22570049 )
2012
22
Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. ( 22571582 )
2012
23
Anti-human milk fat globulin staining of perifollicular xanthomatosis inA Fox-Fordyce disease. ( 23181442 )
2012
24
Histopathology attributes of Fox-Fordyce disease. ( 23067079 )
2012
25
Fox-Fordyce disease. ( 23286818 )
2012
26
Fox-Fordyce disease in monozygotic female twins. ( 21679831 )
2011
27
Fox-Fordyce Disease (Apocrine Miliaria). ( 21751451 )
2011
28
Fox-Fordyce disease following axillary laser hair removal. ( 21576577 )
2011
29
Fox-Fordyce disease exacerbated by hyperhidrosis. ( 20537067 )
2010
30
Fox-Fordyce disease in daughter and father. ( 19060475 )
2009
31
Dilation of apocrine glands. A forgotten but helpful histopathological clue to the diagnosis of axillary Fox-Fordyce disease. ( 19461248 )
2009
32
Clinicopathological study of Fox-Fordyce disease. ( 19712275 )
2009
33
Pruritic axillary papules. Fox-Fordyce disease. ( 18619083 )
2008
34
Perifollicular xanthomatosis as the hallmark of axillary Fox-Fordyce disease: an evaluation of histopathologic features of 7 cases. ( 18711075 )
2008
35
Pimecrolimus is effective in Fox-Fordyce disease. ( 16961542 )
2006
36
Fox fordyce disease in a prepubertal girl. ( 15660912 )
2005
37
Patterns histopathologic of Fox-Fordyce disease. ( 15618931 )
2004
38
Axillary perifollicular xanthomatosis resembling Fox-Fordyce disease. ( 15068468 )
2004
39
Axillary perifollicular xanthomatosis resembling Fox-Fordyce disease. ( 15527440 )
2004
40
Apoeccrine sweat duct obstruction as a cause for Fox-Fordyce disease. ( 12637930 )
2003
41
Fox-Fordyce disease. ( 12705772 )
2003
42
Axillary Fox-Fordyce disease treated with liposuction-assisted curettage. ( 11939804 )
2002
43
Fox-Fordyce disease. ( 12041809 )
2002
44
Fox-Fordyce disease: diagnosis with transverse histologic sections. ( 10607326 )
2000
45
Fox-Fordyce disease: two cases in patients with Turner syndrome. ( 10086869 )
1999
46
Fox-Fordyce disease in two prepubertal girls: histopathologic demonstration of eccrine sweat gland involvement. ( 8844748 )
1996
47
Fox-Fordyce disease treated with topical clindamycin solution. ( 7574824 )
1995
48
Fox-Fordyce disease in a male patient--response to oral retinoid treatment. ( 8313643 )
1994
49
Fox-Fordyce disease: successful treatment with topical clindamycin in alcoholic propylene glycol solution. ( 1498406 )
1992
50
Fox-Fordyce disease. ( 28134161 )
1988

Variations for Fox-Fordyce Disease

Expression for Fox-Fordyce Disease

Search GEO for disease gene expression data for Fox-Fordyce Disease.

Pathways for Fox-Fordyce Disease

Pathways related to Fox-Fordyce Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.86 CD68 CEACAM5 KIT

GO Terms for Fox-Fordyce Disease

Molecular functions related to Fox-Fordyce Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine binding GO:0019955 8.62 KIT OSMR

Sources for Fox-Fordyce Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....